Findings

What do systematic reviews say?

94 questions · 94 findings · 8 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 8.5%GRADE not reported 13 · 13.8%Very low 22 · 23.4%Low 17 · 18.1%Moderate 23 · 24.5%High 11 · 11.7%

Bisphosphonates vs placebo/observation

Infusion‐related events · women with early breast cancer

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 7 participants
Moderate

Bisphosphonates vs placebo/observation

Bone metastases · women with advanced breast cancer without bone metastases

Bisphosphonates showed no clear difference in bone metastases compared with placebo/observation (moderate certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 0.96 [0.65, 1.43]
3 studies · 330 participants
Moderate

Bisphosphonates vs placebo/observation

Median time to a skeletal‐related event · women with advanced breast cancer without bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Low

Bisphosphonates vs placebo/observation

Overall survival · women with advanced breast cancer without bone metastases

Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 0.89 [0.73, 1.09]
3 studies · 330 participants
High

Bisphosphonates vs placebo/observation

Quality of life · women with advanced breast cancer without bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 124 participants
Moderate

Bisphosphonates vs placebo/observation

Skeletal‐related event (SRE) · women with metastatic breast cancer with bone metastases

Bisphosphonates leads to lower skeletal‐related event (SRE) compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 0.86 [0.78, 0.95]
9 studies · 2810 participants
High

Bisphosphonates vs placebo/observation

Median time to a skeletal‐related event · women with metastatic breast cancer with bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 2891 participants
High

Bisphosphonates vs placebo/observation

Overall survival · women with metastatic breast cancer with bone metastases

Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (moderate certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 1.01 [0.91, 1.11]
7 studies · 1935 participants
Moderate

Bisphosphonates vs placebo/observation

Bone pain · women with metastatic breast cancer with bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 3297 participants
Moderate

Bisphosphonates vs placebo/observation

Quality of life · women with metastatic breast cancer with bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1888 participants
Moderate

Bisphosphonates vs placebo/observation

Overall survival · women with early breast cancer

Bisphosphonates leads to lower overall survival compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
HR 0.91 [0.83, 0.99]
9 studies · 13949 participants
High

Bisphosphonates vs placebo/observation

Overall survival postmenopausal women · women with early breast cancer

Bisphosphonates leads to lower overall survival postmenopausal women compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
HR 0.77 [0.66, 0.9]
4 studies · 6048 participants
High

Bisphosphonates vs placebo/observation

Overall survival: pre‐ or perimenopausal women · women with early breast cancer

Bisphosphonates showed no clear difference in overall survival: pre‐ or perimenopausal women compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
HR 1.03 [0.86, 1.22]
2 studies · 3501 participants
High

Bisphosphonates vs placebo/observation

Disease‐free progression · women with early breast cancer

Bisphosphonates showed no clear difference in disease‐free progression compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
HR 0.94 [0.87, 1.02]
7 studies · 12578 participants
High

Bisphosphonates vs placebo/observation

Disease‐free progression: postmenopausal women · women with early breast cancer

Bisphosphonates leads to lower disease‐free progression: postmenopausal women compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
HR 0.82 [0.74, 0.91]
7 studies · 8314 participants
High

Bisphosphonates vs placebo/observation

Disease‐free progression: pre‐ or perimenopausal women · women with early breast cancer

Bisphosphonates showed no clear difference in disease‐free progression: pre‐ or perimenopausal women compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
HR 1.01 [0.9, 1.13]
4 studies · 5493 participants
High

Bisphosphonates vs placebo/observation

Incidence of fractures · women with early breast cancer

Bisphosphonates showed no clear difference in fracture incidence compared with placebo/observation (moderate certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 0.77 [0.54, 1.08]
6 studies · 7602 participants
Moderate

Bisphosphonates vs placebo/observation

Adverse events: osteonecrosis of the jaw · women with early breast cancer

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 13242 participants
High

Bisphosphonates vs placebo

Number of participants with change in bone pain (disappearance of pain)¹assessed on VAS · Paget's disease of bone

Bisphosphonates probably leads to higher number of participants with change in bone pain (disappearance of… compared with placebo (moderate certainty).

1 finding from 1 review

Bisphosphonates for Paget's disease of bone in adults 2017 · Cochrane Headline outcomes only
RR 3.42 [1.31, 8.9]
2 studies · 205 participants
Moderate

Bisphosphonates vs placebo

Number of participants who experienced radiologically‐confirmed fractures · Paget's disease of bone

It is very uncertain whether bisphosphonates changes number of participants who experienced radiologically‐confirmed… compared with placebo (very low certainty).

1 finding from 1 review

Bisphosphonates for Paget's disease of bone in adults 2017 · Cochrane Headline outcomes only
RR 0.89 [0.18, 4.31]
4 studies · 356 participants
Very low